Sort   by:  
 Page size 
UnknownDeterminants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor.
Not available
S-EPMC9813003 | biostudies-literature
UnknownSplenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.
Not available
S-EPMC6196105 | biostudies-literature
UnknownTargeted deep sequencing in primary myelofibrosis.
Not available
S-EPMC5737166 | biostudies-literature
UnknownRevised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
Not available
S-EPMC5940654 | biostudies-literature
UnknownMyeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases.
Not available
S-EPMC11873042 | biostudies-literature
UnknownCytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.
Not available
S-EPMC8931050 | biostudies-literature
UnknownClinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias.
Not available
S-EPMC6728219 | biostudies-literature
UnknownOne thousand patients with primary myelofibrosis: the mayo clinic experience.
Not available
S-EPMC3538387 | biostudies-literature
UnknownSystemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System.
Not available
S-EPMC12326232 | biostudies-literature
UnknownU2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Not available
S-EPMC10514309 | biostudies-literature
Sort   by:  
 Page size